| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $100,600,949 ) (Continued on the next page) |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI171186 | Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses | 000 | 2 | NIH | 2/20/2024 | $733,393 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01DK132406 | Characterizing Immunogenetics in Type 1 Diabetes | 000 | 2 | NIH | 3/1/2024 | $514,984 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI176563 | Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization | 000 | 2 | NIH | 2/16/2024 | $723,785 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI173199 | Breastmilk antibodies regulate neonatal immunity to the microbiota | 001 | 2 | NIH | 2/5/2024 | $583,844 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI173199 | Breastmilk antibodies regulate neonatal immunity to the microbiota | 002 | 2 | NIH | 2/21/2024 | $100,392 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI173199 | Breastmilk antibodies regulate neonatal immunity to the microbiota | 000 | 1 | NIH | 11/21/2023 | $32,609 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 000 | 2 | NIH | 12/7/2023 | $1,424,249 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL161037 | Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Cell Transplant Recipients | 001 | 4 | NIH | 12/6/2023 | $678,847 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM144128 | Data analysis tools for leveraging massive public data to improve hypothesis-driven research | 000 | 4 | NIH | 2/16/2024 | $386,491 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 4 | NIH | 11/10/2023 | $112,500 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 4 | NIH | 11/10/2023 | $581,116 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | K23AI163343 | Cytomegalovirus-specific Immune Reconstitution after Hematopoietic Cell Transplantation in the Era of Modern Antiviral Prophylaxis | 000 | 4 | NIH | 1/4/2024 | $189,432 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | K22CA258805 | Targeted disruption of the YAP/TAZ/TEAD axis in pancreatic cancer | 000 | 4 | NIH | 2/29/2024 | $75,600 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM140823 | Mechanisms of transcriptional regulation and transcription factor specificity | 000 | 4 | NIH | 1/24/2024 | $1,009,413 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA255015 | Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma | 000 | 4 | NIH | 2/27/2024 | $362,340 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA249528 | Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance | 000 | 5 | NIH | 12/26/2023 | $362,340 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01NS119650 | Defining cellular states of quiescence in human brain tumors | 000 | 5 | NIH | 12/29/2023 | $463,899 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL148189 | Extrinsic regulation of primitive, myeloid-biased hematopoietic stem cells by Semaphorin 4a | 000 | 5 | NIH | 12/5/2023 | $448,040 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM139429 | Molecular mechanisms and functions of global chromatin control | 000 | 5 | NIH | 12/12/2023 | $732,019 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01NS114222 | Molecular dissection of glia-neuron interactions | 000 | 5 | NIH | 1/5/2024 | $41,485 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01NS114222 | Molecular dissection of glia-neuron interactions | 002 | 5 | NIH | 1/10/2024 | -$41,485 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01NS114222 | Molecular dissection of glia-neuron interactions | 003 | 5 | NIH | 1/24/2024 | -$41,485 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01NS114222 | Molecular dissection of glia-neuron interactions | 001 | 5 | NIH | 1/10/2024 | $41,485 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01NS114222 | Molecular dissection of glia-neuron interactions | 003 | 5 | NIH | 1/24/2024 | $41,485 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HD103571 | Early and Reinfection in High Risk Women | 000 | 30 | NIH | 2/14/2024 | $825,084 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA247548 | Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study | 000 | 5 | NIH | 12/21/2023 | $592,029 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 001 | 6 | NIH | 2/5/2024 | $88,175 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 002 | 6 | NIH | 2/9/2024 | -$88,175 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 000 | 6 | NIH | 2/2/2024 | $427,075 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | K08CA241523 | Therapeutic applications of CD4+ T cells specific for oncogenic driver mutations | 000 | 5 | NIH | 2/20/2024 | $194,107 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA243328 | Tumor-specific autoantibodies for SCLC early detection | 000 | 6 | NIH | 11/15/2023 | $384,742 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA234488 | Role of tumor cell cluster-induced signaling in breast cancer metastasis | 000 | 6 | NIH | 11/22/2023 | $362,340 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI150500 | Mathematical modeling of optimal therapeutic combinations for HIV cure | 000 | 6 | NIH | 11/6/2023 | $419,297 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA240832 | Novel Approaches to CD33-Directed Radioimmunotherapy | 000 | 6 | NIH | 11/15/2023 | $781,727 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA230617 | Hormone signaling and translation control in advanced prostate cancer | 000 | 7 | NIH | 1/5/2024 | $390,548 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA233328 | Hutchinson Center as Lead Academic Participating Site (UG1) | 000 | 6 | NIH | 2/13/2024 | $442,472 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI140891 | Complete mapping of immune selection from antibodies to HIV | 000 | 7 | NIH | 12/14/2023 | $362,442 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA227092 | Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality | 000 | 6 | NIH | 1/30/2024 | $766,928 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL136135 | Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy | 000 | 9 | NIH | 1/15/2024 | $669,225 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U10CA180819 | SWOG Statistics and Data Management Center | 001 | 11 | NIH | 3/4/2024 | $7,220,289 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 000 | 19 | NIH | 11/2/2023 | $607,963 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 000 | 19 | NIH | 11/2/2023 | $205,688 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern | 003 | 19 | NIH | 11/14/2023 | $9,774,636 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern | 003 | 19 | NIH | 11/14/2023 | $699,896 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern | 003 | 19 | NIH | 11/14/2023 | $250,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern | 003 | 19 | NIH | 11/14/2023 | $500,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3008 2022-2023 | 001 | 19 | NIH | 11/16/2023 | $9,074,980 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern - LC GY18 | 000 | 19 | NIH | 11/8/2023 | $9,067,449 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3008 2022-2023 | 001 | 19 | NIH | 11/16/2023 | $6,921,265 |
|